肺力咳合剂在非重症社区获得性肺炎治疗中的应用评估  

Application evaluation of Feilike mixture in the treatment of non-severe community-acquired pneumonia

作　　者：王镇[1] 胡晓冬[1] 张宇锋[1] WANG Zhen;HU Xiaodong;ZHANG Yufeng(Department of Pulmonary Diseases,Jiangyin Hospital Affiliated to Nanjing University of Chinese Medicine,Jiangsu,Wuxi 214400,China)

机构地区：[1]南京中医药大学江阴附属医院肺病科,江苏无锡214400

出　　处：《中国医药科学》2024年第22期142-145,共4页China Medicine And Pharmacy

基　　金：江苏省中医药管理局科技发展项目(MS2022060);南京中医药大学自然科学基金项目(XZR2023081)。

摘　　要：目的本研究旨在评估肺力咳合剂在非重症社区获得性肺炎(CAP)患者中辅助抗生素治疗的疗效。方法选取南京中医药大学江阴附属医院2021年6月至2022年12月收治的80例非重症CAP患者,根据随机数表法将其分为对照组(n=40)和观察组(n=40)。对照组仅接受抗生素治疗,观察组接受抗生素及肺力咳合剂联合治疗,两组治疗时间约为1周。主要观察指标包括临床疗效、临床症状改善时间、治疗前后炎症递质水平、治疗后生活质量评价及不良反应发生情况等。结果观察组临床总有效率为87.5%,高于对照组的77.5%,差异无统计学意义(P>0.05);但观察组发热消退、咳嗽好转及肺啰音消失时间较对照组短,差异有统计学意义(P<0.05);观察组治疗后C反应蛋白、白细胞水平分别为(20.732±4.786)mg/L、(6.763±1.251)×10^(9)/L,分别低于对照组(25.977±5.077)mg/L、(7.953±1.248)×10^(9)/L,差异有统计学意义(P<0.05);观察组治疗后的生活质量评分为(83.77±4.53)分,高于对照组的(76.83±5.97)分,差异有统计学意义(P<0.05);两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论在非重症社区获得性肺炎的治疗中,佐用肺力咳合剂可以有效促进临床症状缓解,改善胸部影像学表现,降低相关炎症指标水平,并有助于提高治疗效果和提高生活质量。因此,该治疗方案在实际临床中具有一定的推广应用价值。Objective To evaluate the efficacy of Feilike mixture in adjuvant antibiotic therapy in patients with non-severe community-acquired pneumonia(CAP).Methods A total of 80 patients with non-severe CAP admitted to Jiangyin Hospital of Traditional Chinese Medicine from June 2021 to December 2022 were selected and divided into the control group(n=40)and the observation group(n=40)according to the random number table method.The control group was only treated with antibiotic therapy,while the observation group was treated with antibiotic therapy combined with Feilike mixture.The treatment time of both groups was about 1 week.The clinical efficacy,time for improvement of clinical symptoms,levels of inflammatory mediators before and after treatment,evaluation of quality of life(QoL)after treatment,and incidence of adverse reactions(ADRs)were included as the main observation indicators.Results The overall response rate in the observation group was 87.5%,higher than 77.5%in the control group,without statistically significant difference(P>0.05).However,the time for fever resolution,cough improvement,and lung rale disappearance in the observation group were shorter than the control group,respectively,with statistically significant differences(P<0.05).After treatment,the levels of C-reactive protein and white blood cells in the observation group were(20.732±4.786)mg/L and(6.763±1.251)×10^(9)/L,lower than(25.977±5.077)mg/L and(7.953±1.248)×10^(9)/L in the control group,respectively,with statistically significant differences(P<0.05).After treatment,the QoL score of the observation group was(83.77±4.53)points,higher than(76.83±5.97)points of the control group,with statistically significant difference(P<0.05).Meanwhile,there was no statistically significant difference in the incidence of ADRs between the two groups(P>0.05).Conclusion In the treatment of non-severe CAP,Feilike mixture can effectively promote the relief of clinical symptoms,improve chest imaging manifestations,reduce the level of related inflammatory indicato

关 键 词：肺力咳合剂 社区获得性肺炎 临床疗效 中医药治疗 

分 类 号：R563.1[医药卫生—呼吸系统]